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1. Introduction 
The Lewis blood-group system comprises 5 anti- 
gens - Lea, Le b, Lee, Le d and Lex [19]. In investiga- 
tions on the molecular structures of different blood- 
group Lewis active glycosphingolipids from human 
plasma nd red cells, the Le a, Leb and LedH antigens 
could be identified as being lacto-N-fucopentaosyl(II)- 
ceramide, lacto-N-difucohexaosyl(I)ceramide and 
lacto-N-fucopentaosyl(I)ceramide, respectively [ 1-5]. 
The Le x property is probably based on a particular 
specificity of the anti-Le x antibodies rather than a 
distinct antigenic determinant; i  has been shown that 
anti-Le x binds to the Lewis core disaccharide 
Fucal~4GlcNAc-R [8], a property which enables the 
antibody to react with both Lea and Leb determinants. 
This specificity may render the antibody less sensitive 
to steric effects, and thus able to bind even to the 
traces of Lea substance present on cord red cells. As 
Lea of Lewis-positive non-secretors can be regarded at 
least formally as the precursor of I~ b in Lewis-posi- 
tive secretors, and since it is now well-established that 
the Le dH antigen of Le(a-b-)  secretors can be referred 
to H type 1 glycosphingolipid [3-5], it would be a 
matter of logical consequence to suggest that the Le c 
antigen detected on the red cells of Le(a-b- )  non- 
secretors might be lacto-N-tetraosylceramide, the pre- 
cursor of the H type 1 (LedH)antigen (see also [6]). 
In contrast to this consideration, based on a weak 
inhibition capacity of 3'-fucosyllactose, Watkins pro- 
posed the structure Gal~l-*4GlcNAc3+-lo~Fuc for the 
Le c determinant (see [9]). This result was recently 
confirmed by similar inhibition studies [17]. 
This paper describes our latest immunochemical 
experiments on the Le c antigenicity and represents a 
critical re-examination f these hypotheses. 
2. Materials and methods 
Abbreviations and trivial names: Glc, glucose; Gal, galactose; 
GlcNAc,N-acetylghicosamine; Fuc,fucose; Cer, ceramide; lacto- 
N-tetraosylceramide, Galgl-*3GlcNAc# l~3GalBl~4Glc# I--, I 
Cer; lacto-N-neotetraosylceramide, GalB1--,4GIcNAc#I~ 
3Gal~l--~4Glc#l---}l Cer; H type 1 (LedH), blood-group active 
lacto-N-fucopentaosyl(l)ceramide, Fucal~2Galgl~ 
3GlcNAc#I~3Galgl~4GIc#I~I Cer; Le a blood-group active 
lact o-N-fucopen tao syl(l I)ceramide, Gal# I~3GlcNAc- 
(4,--laFuc)/~l--,3Galgl--,4Glc#l--}l Cer; lacto-N-fucopentaosyl- 
(Ill)ceramide, Galgl--+4GlcNAc(3,--laFuc)fl l~3Galfl 1~ 
4Glc#l~l Cer; Y-fucosyllactose, Galgl--,4Glc3,--lc~Fuc; 
apoHDL, delipidated human high-density lipoprotein; 
HPTLC, high-performance thin-layer chromatography 
This paper is the seventh of a series on the immunochemistry 
of the blood-group Lewis system [1-5,8] 
2.1. Glycosphingolipids 
Lacto-N-neotetraosylceramide was prepared from 
human erythrocyte membranes a in [10]. It was also 
obtained from rabbit erythrocyte ceramide pentasac- 
charide by t~-galactosidase tr atment [ 11,12]. H type 1 
(Le dH) blood-group active lacto-N-fucopentaosyl(I)- 
ceramide was isolated, purified and identified as in 
[3-5]. It was degraded to lacto-N-tetraosylceramide 
by mild acid hydrolysis with 0.1 M trichloracetic acid 
at 100 °C for 2 h. Purification was performed by pre- 
parative silica gel HPTLC [ 1 ]. Le a blood-group active 
lacto-N-fucopentaosyl(II)ceramide was isolated from 
human plasma s described previously. 
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2.2. Enzymes 
A mixture of a l~3 and Lewis-gene-dependent 
a l~4 fucosyltransferases wa obtained from human 
milk by ammonium sulphate fractionation and 
CM-cellulose chromatography as in [14]. Two differ- 
ent preparations (I and II) were used here. 
od->3/4 and ctl-~2 fucosidase were purified from 
an ultrasonic extract of Trichomonas foetus by frac- 
tionation on Sepharose 4B followed by chromatogra- 
phy on DEAE-cellulose [13], the enzymes being 
eluted with 0.7 M and 0.15 M KC1, respectively. 
2.3. Biosynthesis ofglycosphingolipids 
GDP-fucose was prepared as in [ 15]. Delipidated 
human high density lipoprotein (apoHDL) was a gen- 
erous gift from Professor Gerd Assmann (Zentrallabor 
und Abt. f~r klinische Chemie, University of Mfinster). 
Lactotetraosylceramide (100 pg) or neolactotetra- 
osylceramide (100/ag) recombined with apoHDL as 
in [12] and dialyzed against 50 mM Tris-HC1 buffer 
(pH 7.0) for 4 h, were incubated for 46 h at 37°C 
with the al~3/al-->4 fucosyltransferase pr paration 
(15 mg protein) in the presence of 2 pmol MgC12 and 
0.2 pmol GDP-fueose and mixed continuously with a 
magnetic stirring bar, the total volume being 300 pl. 
The extraction of the glycolipids was performed as 
described in the following section. 
2.4. Enzymatic degradation 
Fucolipid (100 pg) was recombined with 200 pg 
apoHDL as in [ 12]. The resulting lycolipid-lipopro- 
tein complex was incubated with different fucosidases 
for 18 h at 37°C in 50 mM Tris-HC1 buffer (pH 7.0). 
Subsequently 4 vol. chloroform/methanol (2/1, v/v) 
were added, and the mixture was vigorously agitated. 
After centrifugation a d removal of the lower phase, 
the remaining upper phase was extracted again with 
theoretical lower phase. The combined lower phases 
were evaporated to dryness and used for HFFLC and 
immunological investigations. 
2.5. Antisera 
Anti-Le a sera and anti-Le b sera were purchased 
from Ortho Diagnostic Systems, Raritan (goat), 
Behring, Marburg (goat), and Molter, Heidelberg 
(human). Human anti-Le cwas obtained from the 
blood donor 'ARM' [9]. Animal anti-Le cwas prepared 
by immunization of goats as in [ 16], using blood- 
group substances from boiled saliva of Le(a-b-)  non- 
secretors as immunogen [6]. 
2.6. Immunological methods 
Haemagglutination nhibition and passive haemag- 
glutination tests were performed as in [ 1 ], except that 
for haemagglutination nhibition tests using anti-Le c
'ARM', erythrocytes from O Le(a-b-)  non-secretors 
were treated with papain. Incubation of packed eryth- 
rocytes (100 pl) in 500 pl phosphate-buffered saline 
(pH 7.4) containing 0.01% papain (Merck, Darmstadt) 
for 5 min at 37°C, was determined toyield a maximum 
agglutination strength of Le(a-b-)  cells from non- 
secretors without simultaneous agglutination oferyth- 
rocytes of all other Lewis and secretor phenotypes. 
3. Results and discussion 
To investigate whether the antigenic determinant 
of the Le c property might reside in type 2 chain 
glycolipids, haemagglutination nhibition and passive 
haemagglutination tests were performed with lacto-N- 
fucopentaosyl(III)ceramide and its precursor, lacto-N- 
neotetraosylceramide. Th  lacto-N-fucopentaosyl(III)- 
ceramide was prepared by enzymatic transfer of fucose 
onto lacto-N-neotetraosylceramide. In fig l, lanes 8 
and 9 demonstrate he results of the incubation of 
lacto-N-neotetraosylceramide with 2 different prepa- 
rations of al-+3/al~4 fucosyltransferase of human 
milk in the presence of GDP-fucose. In both cases a 
glycolipid was produced which had a HPTLC migration 
behaviour very similar to, but definitely distinct from 
that of the Lea-I glycolipid (nomenclature in [ 1-3]). 
These glycolipid fractions, as well as their precursor, 
lacto-N-neotetraosylceramide, failedto show even 
partial inhibition of 4 haemagglutinating units of 
anti-Le c 'ARM' or goat anti-Le c, 50 pg substance being 
used for each assay. Furthermore, coating of 9 × 107 
O Le(a-b+) erythrocytes with 50 pg of these glyco- 
lipids did not render the cells agglutinable by either 
of the 2 Le c antisera. 
These results provide good evidence that the 
3'-fucosyllactosamine as well as its corresponding 
type 2 chain precursor, N-acetyllactosamine, canbe 
excluded as a possible molecular basis of the Le c 
antigen. 
To investigate the hypothesis that type 1 chain 
glycolipids are involved in the Le c antigenici W, the 
following experiments were performed: after mild 
acid hydrolysis of the H type 1 (Le dH) blood-group 
active lacto-N-fucopentaosyl(I)ceramide (Le H-I, fig.l, 
lane 1) a degradation product was obtained which 
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showed a slightly faster migration behaviour than 
lacto-N-neotetraosylceramide (f g.l, lane 3). This sub- 
stance, regarded as lacto-N-tetraosylceramide, was also 
investigated for its ability to inhibit the anti-Le c sera. 
Using 4 haemagglutinating units of either anti-Le c
'ARM' or goat anti-Le c and erythrocytes from an 
Le(a-b--c+) donor, no complete or incomplete inhi- 
bition of agglutination by 30/ag glycolipid was 
achieved with either antiserum. Likewise tests of  
quantitative passive haemagglutination failed to reveal 
any Le c activity of  the degradation product. These 
results are not in accordance with [ 18]: upon immuni- 
zation of rabbits with GaI~I~3GlcNAc coupled to 
bovine serum albumin they obtained an antiserum 
which after purification by appropriate affinity col- 
umns agglutinated the erythrocytes of a Le(a -b - )  
non-secretor but not those from Le(a+b-), Le(a-b+), 
or Le (a -b - )  secretor individuals. This apparent con- 
tradiction led us to consider that our substance pre- 
pared from H type 1 (Le dH) glycolipid might be 
~ ° 
I 2 3 4 5 6 7 8 9 10 
Fig.1. High-performance thinqayer chromatography of glycosphingolipid fractions obtained after incubation of lacto-N-fucopen- 
taosyl(I)ceramide (H type 1 (LedH)), lacto-N-tetraosylceramide (LNT-Cer), lacto-N-fucopentaosyl(II)ceramide (Lea), and lacto-N- 
neotetraosylceramide (LNneoT-Cer) with different fucosidases or fucosyltransferases: (1) H type 1 (LedH); (2) H type 1 (Le dH) 
after treatment with al~2 fucosidase in the presence of apoHDL; (3) LNT-Cer; (4) Le a after treatment with al~4 fucosidase in
the presence of apoHDL; (5) LNT-Cer; (6) Lea; (7) LNT-Cer after incubation with al~3/ctl--.4 fucosyltransferase (preparation I) 
in the presence of apoHDL and GDP-fucose; (8) LNneoT-Cer after incubation with al~3/al~4 fucosyltransferase (preparation 1)
in the presence of apoHDL and GDP-fucose; (9) LNneoT-Cer after incubation with al~3/al~4 fucosyltransferase (preparation II) 
in the presence of apoHDL and GDP-fucose; (10) LNneoT-Cer (not completely purified). 
Abbreviations." lacto-N-tetraosylceramide, GalBl~3GlcNAcgl~3GalBl~4Glc#l~l Cer; lacto-N-neotetraosylceramide: Gal#l~ 
4GIcNAcBI~3GaI#I--,4GIc#I~I Cer; lacto-N-fucopentaosyl(II)ceramide (Lea), GalBl~3GlcNAc(4*--laFuc)fl~3GalBl~4Glc#l~l 
Cer; H type 1 (LedH), Fucal~2GalBI-~3GIcNAcBI~3GalBI~4GIc#I~I Cer 
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misidentified or, an artifact. The structure of the deg- 
radation product was therefore checked by a number 
of methods: 
(1) 360 MHz 1H NMR spectroscopical analysis yielded 
spectra, with a signal pattern in complete accord 
with the structure of a lacto-N-tetraosylceramide 
[5]. In addition, data obtained by spin decoupling 
difference spectroscopy and nuclear Overhouser 
enhancement represent direct proof of the above 
structure [5]. The resonances obtained showed 
no evidence of contamination by impurities [5]. 
(2) Treatment of LedH-I with ctl~2 fucosidase from 
Trichomonas foetus yielded a glycolipid showing 
a migration behaviour identical to that of the 
degradation product obtained by chemical 
hydrolysis (fig.l, lane 2 and 3 respectively). 
(3) Degradation of Le a substance (Lead glycolipid) 
with al--~4 fucosidase from Trichomonas foetus 
yielded a glycolipid with a migration behaviour 
which was also identical to that obtained by 
chemical or enzymatic degradation of LedH-I 
(fig.l, lane 4). 
(4) Furthermore, LedH-I pre-degraded by acid hydrol- 
ysis and subsequently incubated with the ke-gene 
dependent al-+4 fucosyl-transferase yi lded a 
Le a blood-group active glycolipid which had an 
RF-value identical to that of Lea-I (fig.l, lane 7). 
These experiments unambiguously show, that the 
substance obtained from LedH-I by chemical degrada- 
tion is lacto-N-tetraosylceramide and that also this 
glycolipid does not represent the Le c antigen. 
Considering the investigations in [ 18] it seems most 
reasonable to propose that the Le c antigen has a type 1 
oligosaccharide core with at least one additional sugar 
unit linked to the lacto-N-tetraosylceramide. I ntifi- 
cation studies, i.e., purification and structural elucida- 
tion of the Le c glycolipid are now in progress. 
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